Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: Attaining selectivity versus PDE6
- 30 December 2005
- journal article
- research article
- Published by Wiley in Medicinal Research Reviews
- Vol. 26 (3) , 369-395
Abstract
The role of phosphodiesterase type 5 (PDE5) in the mechanism of male erection has been well understood, and several drugs inhibiting this enzyme are being used for the treatment of erectile dysfunction (ED). Discovery of inhibitors with improved selectivity versus other PDE isozymes could lead to drugs with improved safety profile. Achievement of selectivity versus PDE6, co‐inhibition of which results in disturbances of color perception, remains the most challenging aspect of current drug discovery programs. The present review describes several case studies, where significant (>100 fold) selectivity versus PDE6 has been attained via investigation of structure–activity relationships (SAR). Special attention is given to the chemical routes leading to novel chemotypes and allowing efficient exploration of their SAR's. Strategies for attaining inhibitor selectivity discussed below may be applicable for other drug discovery programs. © 2005 Wiley Periodicals, Inc. Med Res RevKeywords
This publication has 84 references indexed in Scilit:
- SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunctionBioorganic & Medicinal Chemistry Letters, 2004
- Synthesis and biological activities of novel β-Carbolines as PDE5 inhibitorsBioorganic & Medicinal Chemistry Letters, 2003
- Identification of Three Alternative First Exons and an Intronic Promoter of Human PDE5A GeneBiochemical and Biophysical Research Communications, 2000
- Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunctionBioorganic & Medicinal Chemistry Letters, 1996
- Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3′,5′-Cyclic Nucleotide PhosphodiesterasesJournal of Biological Chemistry, 1996
- Zaprinast, cicletanine, and verapamil attenuate overdrive pacing-induced myocardial ischemia in conscious rabbitsLife Sciences, 1993
- Nitric Oxide: A Physiologic Mediator of Penile ErectionScience, 1992
- Apparent multiple forms of cyclic AMP phosphodiesterase from rat erythrocytesMolecular and Cellular Endocrinology, 1976
- Inhibition of separated forms of phosphodiesterases from pig coronary arteries by uracils and by 7-substituted derivatives of 1-methyl-3-isobutylxanthineJournal of Medicinal Chemistry, 1976
- Studies on the Mechanism of Hormone ActionScience, 1972